S 227928
Alternative Names: S-227928Latest Information Update: 26 Aug 2024
Price :
$50 *
At a glance
- Originator Servier; Vernalis
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action MCL1 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 21 Aug 2024 Servier plans a phase I/II trial for Acute myeloid leukemia, Myelodysplastic syndrome and Chronic myelomonocytic leukemia (Combination therapy, Monotherapy, Second line therapy or greater) in November 2024 (IV, Infusion) (NCT06563804)
- 16 Feb 2024 Preclinical trials in Haematological malignancies in France (IV), before February 2024 (Servier pipeline, February 2024)
- 16 Feb 2024 Preclinical trials in Haematological malignancies in United Kingdom (IV), before February 2024 (Servier pipeline, February 2024)